{"id":2227,"date":"2007-09-03T14:45:18","date_gmt":"2007-09-03T13:45:18","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2227"},"modified":"2013-09-12T16:50:59","modified_gmt":"2013-09-12T16:50:59","slug":"saquinavirr-vs-lopinavirr-in-treatment-naive-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2227","title":{"rendered":"Saquinavir\/r vs lopinavir\/r in treatment-naive patients"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Francois Raffi from University Hospital, Nantes, France, presented interim results (24 week) from the Gemini study, which randomised 337 treatment-naive patients to twice daily regimen of SQV\/r (1000mg\/100mg BID) or standard dose lopinavir\/r BID.<\/strong> [1]<\/p>\n<p>Baseline viral load and CD4 count were balanced between each arm (approximate median (range) of 5.2 logs (4.0\u00967.0) and 137 cells\/mm3 (1\u0096580) respectively). Baseline viral load was &gt;100,000 copies\/mL in 67% &#8211; 63% patients.<\/p>\n<p>Virological responses were similar with 89% and 69% patients in each arm suppressed to &lt;400 and &lt;50 copies\/mL respectively. Virological failure occurred more frequently in the saquinavir arm (10\/166, 6% vs 3\/171, 1.8%) and new PI resistance was only reported in two patients in the saquinavir arm.<\/p>\n<p>Lipid data, presented in a poster from Sharon Walmsley, showed that total cholesterol, LDL and HDL all increased by a similar amount in the SQV\/r and LPV\/r arms (by approximately +180, +100 and +45mg\/dL respectively), with triglycerides increasing slightly less in the saquinavir arm (+129 vs +161 mg\/dL). [2]<\/p>\n<p>A higher percentage of patients using lopinavir\/r had lipid changes that left them over NCEP guidelines for using lipid lowering drugs (1.2 vs 8.9% for cholesterol and 21.5 vs 26.8% for triglycerides).<\/p>\n<p>As with previous presentations of this study, 48-week results are needed to know the clinical importance of these differences in a head-to-head study.<\/p>\n<p>References:<\/p>\n<ol>\n<li>Raffi F, Ward D, Ruxrungtham K et al. Saquinavir\/r (SQV\/r) BID vs lopinavir\/r (LPV\/r) BID plus emtricitabine\/tenofovir (FTC\/TDF) QD as initial therapy in HIV-1 infected patients: the Gemini Study. 4th IAS Conference, Sydney, 2007. Abstract WEPEB027.<br \/>\n<a href=\"http:\/\/www.ias2007.org\/pag\/Abstracts.aspx?AID=4318\">http:\/\/www.ias2007.org\/pag\/Abstracts.aspx?AID=4318<\/a><\/li>\n<li>Walmsley S, Bredeek U, Avihingsanon A et al. Evaluation of the impact of highly active antiretroviral therapy (HAART) on lipid profiles \u0096 data from the 24-week interim analysis of the Gemini Study: saquinavir\/r (SQV\/r) BID vs lopinavir\/r (LPV\/r) BID plus emtricitabine\/tenofovir (FTC\/TDF) QD in ARV-naive HIV-1-infected patients. 4th IAS Conference, Sydney, 2007. Abstract TUPEB069. <a href=\"http:\/\/www.ias2007.org\/pag\/Abstracts.aspx?AID=4617\"><br \/>\nhttp:\/\/www.ias2007.org\/pag\/Abstracts.aspx?AID=4617<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Francois Raffi from University Hospital, Nantes, France, presented interim results (24 week) from the Gemini study, which randomised 337 treatment-naive patients to twice daily regimen of SQV\/r (1000mg\/100mg BID) or standard dose lopinavir\/r BID. [1] Baseline &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[92],"class_list":["post-2227","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-ias-4th-2007"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2227"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2227\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}